康龙化成：2026年04月29日投资者关系活动记录表附件之演示文稿(英文版)
FirstQuarterlyResults
2026
Stock code: 300759.SZStock code: 3759.HK
April2026
DisclaimerThedocuments,opinionsandmaterialspresentedinthispresentation(the“Document”)havebeenpreparedbyPharmaronBeijingCo.,Ltd.(康龍化成(北京)新藥技術股份有限公司)(the“Company”)foruseinpresentationsbytheCompanyanddoesnotconstitutearecommendationregardingthesecuritiesoftheCompany.YoufullyunderstandthattheDocumentisbeingmadeavailableonaconfidentialbasisandsubjecttothefollowingprovisions.ThecontentsofthisDocumenthavenotbeenreviewedbyanyregulatoryauthorityinanyjurisdiction.ThedistributionofthisDocumentincertainjurisdictionsmayberestrictedbylaw,andtherecipientsintowhosepossessionthisDocumentcomesshouldinformthemselvesabout,andobservesuchrestrictions.ByaccessingthisDocument,youareagreeing(i)thatyouhavereadandagreetocomplywiththecontentsofthisnoticeanddisclaimerand(ii)tomaintainabsoluteconfidentialityregardingtheinformationdisclosedinthisDocument.ThisDocumenthasnotbeenindependentlyverifiedandisnotintendedtoformthebasisofanyinvestmentdecision.Itdoesnotconstituteanofferorinvitationtosell,oranysolicitationofanyoffertosubscribefororpurchaseanysecuritiesinanyjurisdictioninwhichthemakingofsuchoffer,solicitationorsalewouldbeunlawfulpriortoregistrationorqualificationunderthesecuritieslawsofsuchjurisdictionorwouldnototherwisebeincompliancewiththelawsandregulationsofsuchjurisdiction,andnothingcontainedhereinshallformthebasisofanyinvestmentdecision,contractorcommitmentwhatsoever.ThisDocumentcontainsnoinformationormaterialwhichmayresultinitbeingdeemed(1)tobeanadvertisement,invitationordocumentcontaininganadvertisementorinvitationfallingwithinthemeaningofsection103oftheSecuritiesandFuturesOrdinance(Chapter571oftheLawsofHongKong)(the“SecuritiesandFuturesOrdinance”)or(2)inHongKongtohaveeffectedanoffertothepublicwithoutcompliancewiththelawsofHongKongorbeingabletoinvokeanyexemptionavailableunderthelawsofHongKong,andissubjecttomaterialchangewithoutnotice.ThesecuritiesoftheCompanyhavenotbeenandwillnotberegisteredundertheU.S.SecuritiesActof1933,asamended(the“U.S.SecuritiesAct”),orunderthelawsofanystateoftheUnitedStates.ThisDocumentdoesnotconstituteorformapartofanyofferorsolicitationtopurchaseorsubscribeforsecuritiesintheUnitedStatesandisnotfordistributionandmaynotbedistributed,directlyorindirectly,inorintotheUnitedStates(includingitsterritoriesandpossessions,anystateoftheUnitedStatesandtheDistrictofColumbia).ThesecuritiesoftheCompanywillnotbeofferedorsoldintheUnitedStatesexceptpursuanttoanexemptionfrom,orinatransactionnotsubjecttotheregistrationrequirementsoftheU.S.SecuritiesAct.TherewillbenopublicofferoftheCompany’ssecuritiesintheUnitedStates.ThisDocumentandtheinformationcontainedhereinaswellasinformationpresentedorallyorotherwisearestrictlyconfidentialandmustbetreatedassuch.NeithertheinformationcontainedinthisDocumentnoranycopyhereofmaybe,directlyorindirectly,takenortransmittedintoordistributedintheUnitedStates,Canada,Australia,Japan,PRC,HongKongoranyotherjurisdictionwhichprohibitsthesameexceptincompliancewithapplicablesecuritieslaws.AnyfailuretocomplywiththisrestrictionmayconstituteaviolationofU.S.orotherjurisdiction'ssecuritieslaws.Uponrequest,therecipientwillpromptlyreturnthisDocumentandanyotherwritteninformationmadeavailableinthepresentation,withoutretaininganycopies.ThisDocumentdoesnotpurporttobecomprehensiveortocontainalltheinformationthatarecipientmayneedinordertoevaluatetheGroup.Norepresentation,warrantyorundertaking,expressorimplied,isgivenand,sofarasispermittedbylaw,noresponsibilityorliabilityisacceptedbyanyperson(fortheavoidanceofdoubt,includingbutnotlimitedto,theCompanyanditsaffiliates,controllingpersons,directors,officers,partners,employees,agents,representativesoradvisersofanyoftheforegoing),withrespecttotheaccuracy,reliability,correctness,fairnessorcompletenessofthisDocumentoritscontents.Theinformationcommunicatedinthispresentationcontainscertainstatementsthatareormaybeforwardlooking.Thesestatementstypicallycontainwordssuchas"will","expects",“intends”,“plansto”and"anticipates"andwordsofsimilarimport.Theseforward-lookingstatementsreflectsthecurrentviewoftheCompanywithrespecttofutureeventsarebasedonanumberofassumptionsabouttheCompany’soperationsandfactorsbeyondtheCompany’scontrolandaresubjecttosignificantrisksanduncertainties,and,accordingly,actualresultsmaydiffermateriallyfromtheseforward-lookingstatements.Inparticular,butwithoutlimitation,norepresentationorwarrantyisgivenastotheachievementorreasonablenessof,andnorelianceshouldbeplacedon,anyassumptions,projections,targets,estimates,forecastsoranyforward-lookingstatementscontainedinthisDocument.EachoftheCompanyanditsaffiliates,controllingpersons,directors,officers,partners,employees,agents,representativesoradvisersofanyoftheforegoingassumesnoobligationtoupdateorotherwiserevisetheseforward-lookingstatementsfornewinformation,eventsorcircumstancesthatoccursubsequenttosuchdates.NoneoftheCompanyandanyofitsaffiliates,controllingpersons,directors,officers,partners,employees,agents,representativesoradvisersofanyoftheforegoingshallhaveanyliability(innegligenceorotherwise)inrespectoftheuseof,orrelianceupon,theinformationcontainedhereinbyyouoranypersontowhomtheinformationhereinisdisclosed.InfurnishingthisDocument,theCompanyanditsaffiliatesundertakenoobligationtoprovideanyadditionalinformationortoupdatethisDocumentoranyadditionalinformationortocorrectanyinaccuracieswhichmay
becomeapparent.
1Q2026 Overview
RMB mm
1Q20261Q2025YoY
Revenue
3,5783,09915.5%
Net Profit
3353069.7%
Non
-IFRS Net Profit40634916.2%
Net Operating Cash Flow
604853-29.1%?New POs: new POs increased by 30%+ YoY?MNC Customers: revenue from TOP20 Pharmasincreased by 48.0% YoY?Cash Flow: increased procurement to support business growth & OCF declined YoY
?Guidance: remain confident in achieving the 2026 revenue growth target of 12–18%
Data are rounded to the nearest million. 1Q2025 and 1Q2026 financials are unaudited
1Q2026 Revenue Compositions
| Biologics & CGT Services, 2% |
China EntitiesRevenue Grew 17.6%Overseas SubsidiariesRevenue Grew 0.3%
China/Overseas Entities
NorthAmerica,61%Europe,18%
China,18%
ROW, 3%
Global Customers
TOP20 PharmasRevenue Grew 48.0%Other CustomersRevenue Grew 9.9%
Diversified Customer Base
NA Revenue Grew 9.6%EU Revenue Grew 10.7%CN Revenue Grew 43.4%
Segments
Revenue Composition
Revenue Composition
Revenue Composition
Revenue Composition
TOP20Pharmas,
19%
Other RepeatCustomers,80%
New Customers,
2%
China
Entities, 89%
OverseasSubsidiaries,11%
1Q2026 Laboratory Services
RMB mm
1Q20261Q2025YoY
Revenue
2,1221,85714.3%
GPM
44.1%45.5%-1.4pct?Rapid YoY growth in bioscience revenue & steady growth in lab chemistry revenue?GPM slightly declined YoY due to FX impact?New POs increased by 20%+ YoY
1Q2026 Small Molecule CDMO Services
?Despite FX headwinds, economies of scale drove YoY GPM improvement?Driven by large-scale production orders, new POs increased by 50%+ YoY
RMB mm
1Q20261Q2025YoY
Revenue
86669325.0%
GPM
31.4%30.4%1.0pct
1Q2026 Clinical Development Services
?Early-stage clinical trial services in US achieved strong revenue growth YoY, while clinicaldevelopment services in CN delivered steady revenue growth YoY?GPM declined due to revenue mix of different projects & competitions in China market
RMB mm
1Q20261Q2025YoY
Revenue
50044711.8%
GPM
7.1%11.8%-4.7pct
1Q2026 Biologics & CGT Services
?Biologics CDMO services achieved rapid revenue growth YoY?Integrated projects had been delivered by end of 2025. In 1Q2026, gene therapy CDMO
revenue & GPM declined YoY
RMB mm
1Q20261Q2025YoY
Revenue
8899-11.0%
GPM
-92.8%-68.9%-23.9pct
R&D Costs as % of Total Revenue
3.9%
3.8%
4.1%
3.9%3.9%
2023202420251Q20251Q2026
Selling and Distribution Expenses as % of Total Revenue
Administrative Expenses as % of Total Revenue
(1)
12.7%
12.8%
12.6%
12.9%
12.6%
2023202420251Q20251Q2026
2.2%
2.1%
2.2%2.2%2.2%
2023202420251Q20251Q2026
2.2%
2.1%
2.2%2.2%2.2%
2023202420251Q20251Q2026
Net Finance Costs as % of Total Revenue
(2)
0.1%
0.9%0.9%
1.0%
1.2%
2023202420251Q20251Q2026
1.Excluding share-based compensation expenses recognized in administrative expenses
2.Net finance costs including interest expenses on bank borrowings and lease liabilities, interest income and bank wealth management products related gains or losses
1Q2026 Expenses for the Period
Expect to Continue to Achieve Positive Free Cash Flow in 2026
2,754
2,577
3,221
2,865
2,041
2,669
2023202420251Q20251Q2026
Net Operating Cash FlowCAPEXData are rounded to the nearest million. 1Q2025 and 1Q2026 financials are unaudited
RMB mm
RMB
mm1Q20261Q2025
Net Profit
335306
Add:
Share-based Compensation Expenses1616Foreign Exchange Related Losses412Realized and Unrealized Losses fromEquity Investments
Amortization of Intangible Assets from Acquisitions
Non
-IFRS Adjusted Net Profit406349
1Q2026 Non-IFRS Adjusted Net Profit
Data are rounded to the nearest million. 1Q2025 and 1Q2026 financials are unaudited
2026 Outlook
The evolving healthcare demands and technological innovations will sustain thedevelopment of our industry. Global customer demand continued to demonstrateresilience, while demand from China customers is showing signs of recovery
Continue to develop our end-to-end, fully integrated and multiple modalities-capableservices platform, further advance our CDMO business model, and deepen theintegration of AI and automation across operations to drive sustained growth
Remainconfident in achieving the 2026 revenue growth target of 12–18%
Disclaimer: These forward-looking statements reflects the current view of the Company with respect to future events are based on a number ofassumptions aboutthe Company’s operations and factors beyond the Company’s control and are subject to significant risks and uncertainties, and, accordingly, actual results may differmaterially from these forward-looking statements
THANKYOU